EyePoint Doses First Patient in Second DURAVYU™ Phase 3 Trial for Wet AMD
The firm is gathering safety and efficacy evidence for its sustained delivery, selective tyrosine kinase inhibitor nAMD treatment. EyePoint Pharmaceuticals…
The firm is gathering safety and efficacy evidence for its sustained delivery, selective tyrosine kinase inhibitor nAMD treatment. EyePoint Pharmaceuticals…
![[Espansione] Highlight 3in1 thumbnail Novel Dry Eye Solutions Breakthroughs from Espansione Group at ESCRS 2024 (1) (1)](https://piemagazine.org/wp-content/uploads/sites/4/2024/12/Espansione-Highlight-3in1-thumbnail-Novel-Dry-Eye-Solutions-Breakthroughs-from-Espansione-Group-at-ESCRS-2024-1-1-579x326.png)
